The use of androgenic‐anabolic steroids (AAS) can be associated with psychiatric symptoms such as insomnia, anxiety and increased aggressiveness. Although dose‐dependent effects have been observed in some controlled studies, this association is not always seen in the ecological use of AAS. This study utilized WADA's steroid profile of suspicious use of AAS, urinary detection of AAS metabolites and measurement of sexual hormones to confirm recent use of AAS in a cohort of 103 bodybuilders (75 males, 28 females). The majority of participants (61.2%) presented symptoms of agitation, insomnia, increased aggressiveness or depression in the last 3 months. About one‐third of participants presented scores on the HAM‐A anxiety scale equivalent to moderate to severe symptoms of anxiety. A minority of participants (12.6%) presented high to moderate scores on the BPQ aggressiveness scale. The majority of participants (73.8%) presented hyperthymic temperament in the BRIEF‐TEMPS scale. There was no significant difference in the presence of psychiatric symptoms between males and females and no association between psychiatric symptoms and estimated weekly doses of AAS. A negative association was observed between scores on the BPQ scale (verbal aggression, anger and total score) and the time of AAS use. We discuss differences of AAS use between male and female bodybuilders and the screening of AAS use in the general population. Our findings highlight the importance of mental health awareness among people using AAS.

The treatment of a man who attempted suicide after experiencing symptoms of anxiety and aggressiveness associated with the use of androgenic-anabolic steroids (AAS) is described. This report includes 30 days of inpatient treatment and a 6-month follow-up. Regular use of fluoxetine apparently prevented the onset of anxiety, depression, aggressiveness, and suicide ideation, even with the concurrent use of AAS. The urinary concentration of androgens, metabolites of AAS, and fluoxetine were monitored through analysis of urinary samples by the Brazilian Laboratory of Doping Control. Our results are congruent with previous findings describing the risk of suicide prompted by AAS use as well as the efficacy of fluoxetine in the treatment of mood disorders associated with the use of anabolic steroids.

Trema micranthum (Cannabaceae) has emerged as a promising new source of cannabinoids, including cannabidiol (CBD). Given the substantial medicinal demand for cannabinoids and the regulatory challenges associated with Cannabis sativa due to the presence of Δ⁹-tetrahydrocannabinol (THC), this study sought to explore the presence of CBD, THC, and their precursors, Δ⁹-tetrahydrocannabinolic acid A (THCA A) and cannabidiolic acid (CBDA), in various parts of Trema micranthum using UHPLC-HRMS/MS (Orbitrap). Extracts from fruits, leaves, inflorescences, and stems were obtained using a methanol/hexane (9:1, v/v) solvent mixture. UHPLC coupled with an Orbitrap mass spectrometer was employed for cannabinoid identification and quantification, with standard mixtures prepared in methanol. The extracts yielded significant quantities, such as 6.6%/g from leaves and 3%/g from fruits. Cannabinoids were detected in fruits, leaves, and inflorescences, with acidic forms (CBDA and THCA A) present in higher concentrations than their neutral counterparts. Notably, leaves contained 4.43 × 10⁻³ µg/g of CBD and 1.05 × 10⁻³ µg/g of THC. These findings, facilitated by high-resolution analytical methods, underscore the potential of Trema micranthum as an alternative source for cannabinoids, guiding future research in this area.

The Cannabis market is experiencing steady global growth. Cannabis herbal extracts (CHE) are interesting and sought-after products for many clinical conditions. The medical potential of these formulations is mainly attributed to neutral cannabinoids, such as cannabidiol (CBD), tetrahydrocannabinol (THC), and cannabinol (CBN), and their non-standardized content poses a significant fragility in these pharmaceutical inputs. High-resolution mass spectrometry portrays a powerful alternative to their accurate monitoring; however, further analytical steps need to be critically optimized to keep up with instrumental performance. In this study, Full Factorial and Box–Behnken designs were employed to achieve a multivariate optimization of CBD, THC, and CBN extraction from human and veterinary commercial CHE using a minimum methanol/hexane 9:1 volume and short operational times. A predictive model was also constructed using the Response Surface Methodology and its accuracy was validated. Agitation and sonication times were identified as the most significant operational extraction parameters, followed by the extraction mixture volume. The final setup of the optimized method represented a significantly faster and cheaper protocol than those in the literature. The selected neutral cannabinoids quantification was conducted using ultra high-performance liquid chromatography coupled to high-resolution tandem mass spectrometry (UHPLC-HRMS/MS) with a precision of <15%, accuracy of 69–98%, sensitivity of 23–39 ng kg⁻¹, and linearity regarding pharmaceutical requirements. State-of-the-art levels of analytical sensitivity and specificity were achieved in the target quantification due to high-resolution mass spectrometry. The developed method demonstrated reliability and feasibility for routine analytical applications. As a proof-of-concept, it enabled the efficient processing of 16 samples of commercial CHE within a three-hour timeframe, showcasing its practicality and reproducibility, and highlighting its potential for broader adoption in similar scenarios for both human and veterinary medicines.

Eperua oleifera Ducke (Fabaceae), commonly known as copaíba-jacaré, is traditionally used for therapeutic purposes, like Copaifera oleoresins. Previous GC-MS studies reported its chemical composition as mainly composed of diterpenic acids, consistent with species of the same genus. Although GC-MS remains widely used for comparing compound retention times and fragmentation patterns, its application to diterpenic acids requires a derivatization step to form methyl esters due to the poor chromatographic performance of carboxylic acids on methyl silicone stationary phases. This step may lead to misinterpretations, especially considering recent findings of naturally occurring methyl esters in oleoresins that may co-elute with derivatized acids. This study aimed to apply more sensitive analytical techniques to identify both target and untargeted compounds. The resin of E. oleifera was analyzed by GC-MS to assess the presence of volatile components. Additionally, UHPLC-HRMS was employed using full-scan MS, data-dependent acquisition (DDA), and parallel reaction monitoring (PRM) in both positive and negative ESI modes. GC-MS confirmed the absence of volatile sesquiterpenes, classifying E. oleifera as a resin. Targeted UHPLC-HRMS detected natural methyl esters of diterpenic acids, while untargeted analysis using Compound Discoverer 3.3 software revealed flavonoids and phenolic compounds not previously reported. These findings support the application of UHPLC-HRMS as a powerful tool in phytochemical studies.

Trema micranthum (L.) Blume is a species from the Cannabaceae botanical family, present all over the tropics. A recent study conducted by our group identified the presence of cannabidiol (CBD), Δ⁹‐tetrahydrocannabinol, cannabidiolic acid, and tetrahydrocannabinolic acid‐A in T. micranthum extracts. Their presence in the plant's fruit, inflorescence, and leaf extracts was detected and quantified. T. micranthum has been identified as a potential new source of cannabinoids such as CBD. The present work focuses on a new Cannabinoid Profiling System (CPS) to present a wide view of cannabinoid chemical composition with several compassionate and modern mass spectrometry (MS) tools. Extracts from fruits, leaves, and inflorescences were obtained using a methanol/hexane (9:1, v/v) solvent mixture. Ultra high‐performance liquid chromatography coupled with high‐resolution tandem MS using targeted and untargeted approaches were used in these approaches. CPS allowed the identification of the 26 cannabinoids in T. micranthum described for the first time in this plant.